EA
IART icon

Evolution Advisers’s Integra LifeSciences IART Stock Holding History

Evolution Advisers’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+5
New +$70 ﹤0.01% 517

Other funds holding IART

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Evolution Advisers's IART Position: Q2 2026 in Review

Evolution Advisers opened a new position in Integra LifeSciences (IART) in Q2 2026: 5 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #517 among its holdings.

212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

  • Evolution Advisers held 5 shares of Integra LifeSciences worth $0 as of Q2 2026.
  • Integra LifeSciences was a new Evolution Advisers position in Q2 2026.
  • Integra LifeSciences made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #517 holding.
  • 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.